BioCentury
ARTICLE | Company News

OncoQuest partners with Tesaro for Phase I/II ovarian cancer combo trial

December 8, 2017 4:21 AM UTC

In October, the OncoQuest Inc. subsidiary of Quest PharmaTech Inc. (TSX-V:QPT) partnered with Tesaro Inc. (NASDAQ:TSRO) to conduct a Phase I/II combination trial of OncoQuest's oregovomab (OvaRex Mab, OvaRex) plus Tesaro's Zejula niraparib to treat recurrent ovarian cancer.

Oregovomab is a high-affinity mAb targeting CA 125. Zejula, an oral PARP inhibitor, is approved in the U.S. to treat ovarian cancer in a maintenance setting following chemotherapy...